excellent, thanks for the input.

First 34 Last

Share
Profile

Follow
drays

202 Posts.

24

18/03/22

21:07

Post #: 60286529
Share

Originally posted by Linsanity: ↑

Hi Dray’s, was the best/if not one of the best q&a sessions yet; more than half of the hour long sess was fielding questions as they arose; general quality of Qs was good.

Presentation wise; excellent slim down version - dot pointed punchy facts; each line was explained. In terms of near term market moving milestones - nothing we don’t know already, except for the the FDA tidbit mentioned above by grimloq, as per screenshot below:

more details to follow, but it’ll likely be a combined phase 1/2 approach over 24 month duration with intervention straight off the bat due to the rare disease cohort.

mum’s the word is the new strategy for PYC, something I endorse and respect as they are seeking to protect IP/long term game

Means we have to tuck these to the bottom drawer as we won’t been getting the lead up firework news that normally (over)excite punters - news flow will suit LT holders now.

The most interesting to take for me was that they got beat by Roche for one of their potential assets during the IP claim/challenge. Seem like we lost 18 months of work/investment there and can sense the disappointment, but the fact that we are playing in the same cell type as a US$300B+ pharma titan speaks untold volumes - The titan was operating in stealth mode hence zero existing literature awareness.

Expand

excellent, thanks for the input.

PYC Price at posting: 9.2¢ Sentiment: Buy Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

OCC

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

PL3

Patagonia looks to raise $2.15M for South American exploration and development

SPR

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

SRL

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

MSB

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

There are more pages in this discussion • 45 more messages in this thread...

First 34 Last

Add PYC (ASX) to my watchlist

(20min delay)
Last 12.0¢		Change -0.005(4.00%)		Mkt cap ! $559.9M

Open	High	Low	Value	Volume
12.5¢	13.3¢	12.0¢	$624.5K	5.016M

Buyers (Bids)

No.	Vol.	Price($)
15	1227634	12.0¢

Sellers (Offers)

Price($)	Vol.	No.
12.5¢	130000	2

View Market Depth

No.	Vol.	Price($)
2	25000	0.125
15	990858	0.120
11	1512061	0.115
14	705188	0.110
14	1247445	0.105

Price($)	Vol.	No.
0.125	241570	3
0.130	322948	4
0.135	539501	7
0.140	1503540	5
0.145	255000	2

Last trade - 16.10pm 09/07/2024 (20 minute delay)

PYC (ASX) Chart

excellent, thanks for the input.

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

Patagonia looks to raise $2.15M for South American exploration and development

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

excellent, thanks for the input.

Top Stories

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

Patagonia looks to raise $2.15M for South American exploration and development

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News